Corcept Therapeutics EBITDA vs. Profit Margin
| CORT Stock | USD 58.81 0.45 0.76% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 108.3 M | Current Value 113.7 M | Quarterly Volatility 68.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.78 | 0.9866 |
|
|
For Corcept Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Corcept Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Corcept Therapeutics Incorporated utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Corcept Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Corcept Therapeutics Incorporated over time as well as its relative position and ranking within its peers.
Corcept |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.464 | Earnings Share 1.26 | Revenue Per Share 6.107 | Quarterly Revenue Growth 0.477 | Return On Assets 0.13 |
The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Corcept Therapeutics Profit Margin vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Corcept Therapeutics's current stock value. Our valuation model uses many indicators to compare Corcept Therapeutics value to that of its competitors to determine the firm's financial worth. Corcept Therapeutics Incorporated is rated second in ebitda category among its peers. It is rated third in profit margin category among its peers . The ratio of EBITDA to Profit Margin for Corcept Therapeutics Incorporated is about 480,159,574 . At this time, Corcept Therapeutics' EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Corcept Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Corcept Profit Margin vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Corcept Therapeutics |
| = | 108.32 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Corcept Therapeutics |
| = | 0.23 % |
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Corcept Profit Margin Comparison
Corcept Therapeutics is currently under evaluation in profit margin category among its peers.
Corcept Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Corcept Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Corcept Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Corcept Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Corcept Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 609 K | 639.5 K | |
| Operating Income | 107.3 M | 112.6 M | |
| Net Income | 106.1 M | 111.4 M | |
| Income Tax Expense | 18.4 M | 19.3 M | |
| Income Before Tax | 124.6 M | 130.8 M | |
| Total Other Income Expense Net | 17.3 M | 18.1 M | |
| Net Income From Continuing Ops | 106.1 M | 111.4 M | |
| Non Operating Income Net Other | 608.4 K | 577.9 K | |
| Net Income Applicable To Common Shares | 116.5 M | 122.3 M | |
| Interest Income | 17.3 M | 18.1 M | |
| Net Interest Income | 17.3 M | 18.1 M | |
| Change To Netincome | 11.4 M | 14.5 M | |
| Net Income Per Share | 1.02 | 1.08 | |
| Income Quality | 1.20 | 0.81 | |
| Net Income Per E B T | 0.85 | 1.03 |
Corcept Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Corcept Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Corcept Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Corcept Therapeutics' important profitability drivers and their relationship over time.
Use Corcept Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corcept Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corcept Therapeutics will appreciate offsetting losses from the drop in the long position's value.Corcept Therapeutics Pair Trading
Corcept Therapeutics Incorporated Pair Trading Analysis
The ability to find closely correlated positions to Corcept Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corcept Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corcept Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corcept Therapeutics Incorporated to buy it.
The correlation of Corcept Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corcept Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corcept Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corcept Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Corcept Therapeutics position
In addition to having Corcept Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Market ETFs Thematic Idea Now
Broad Market ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Market ETFs theme has 62 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Market ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.